
    
      The study is an open-label, multi-center, comparative, cross-over trial in adult patients
      with known or highly suspected CNS pathology who were referred for imaging of the CNS.

      The primary objective of the study is to demonstrate the non-inferiority of gadobutrol (0.075
      mmol/ kg body weight) to gadoterate (0.1 mmol/ kg body weight).
    
  